C
Cytomos
Engages in label-free cell analysis for biomedical research and in-vitro diagnostics
About Cytomos
Cytomos is a biotechnology company specializing in real-time single cell analysis, utilizing dielectric spectroscopy and consumer microelectronics to provide label-free detection of cell attributes. The company serves large biotech and pharmaceutical firms, offering solutions that streamline cell line development by identifying lead clones and predicting high-producing cell lines earlier in the process. Cytomos operates in the bioprocess development market, focusing on productivity, stability, and speed to patient. Its business model involves partnerships with major biotech and pharma companies, leveraging its technology to enhance bioprocess efficiency and reduce development timelines. The company's platform technology is applicable to both ATMPs and Biologics, providing significant potential for cost-effective biotechnologies and economies of scale.
Source: Dealroom company dataAt a glance
- Founded
- 2012
- Headquarters
- Edinburgh, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Scottish Enterprise Growth Investments
Old College Capital
Series A2 investors entered at this stage
Archangels
British Business Bank
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cytomos on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cytomos on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.